Top Markets
#1 Helium Helium +114.48%
#2 MowCat MowCat +88.56%
#3 Seeker Seeker +62.86%
#4 UnifAI Network UnifAI Network +35.32%
#5 TENDIES TENDIES +27.62%
#6 pipedog pipedog +23.28%
#7 Zylo Ecosystem Zylo Ecosystem +21.92%
#8 Pons Pons +21.85%
#9 Bounce Bounce +21.52%
#10 Tensor Tensor +21.02%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
EQRx, Inc. EQRx, Inc.

EQRx, Inc.

EQRX
Rank in Stocks #11212
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating... EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$2.34
Last synced: 2023-11-09
Market Cap
$728.90M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade EQRx, Inc. (EQRX)

Category

Healthcare
Revenue for EQRx, Inc. (EQRX)
Revenue in Aug 2026 TTM: 0
According to EQRx, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for EQRx, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH